Protocolo diagnóstico del paciente inmunocomprometido febril con infiltrados pulmonares

  1. Pérez Galera, S. 1
  2. Girón Ortega, J.A. 1
  3. Pérez Cortés, S. 2
  4. Girón González, J.A. 3
  1. 1 Servicio de Medicina Interna. Hospital Universitario Virgen Macarena. Sevilla. España
  2. 2 Servicio de Enfermedades Infecciosas. Hospital Universitario de Jerez. Cádiz. España
  3. 3 Servicio de Medicina Interna General, Enfermedades Infecciosas y Cuidados Paliativos. Hospital Universitario Puerta del Mar. Cádiz. España
Mostrar afiliacións +
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Ano de publicación: 2022

Título do exemplar: Enfermedades infecciosas (V)

Serie: 13

Número: 53

Páxinas: 3136-3142

Tipo: Artigo

DIALNET GOOGLE SCHOLAR

Outras publicacións en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumo

The introduction of new therapies for oncological and autoimmune diseases as well as the increase in survival of transplanted patients or patients with HIV infection has given rise to an increase in immunocompromised patients who consult for febrile syndrome and pulmonary infiltrates. The etiology of the symptoms includes immune reactions, involvement of the neoplasm itself, or infectious diseases. In the case of infectious diseases, the germs can be similar to those of immunocompetent patients. However, we often find other opportunistic pathogens (Listeria spp., Nocardia spp., Pneumocistis jirovecii, or Apergillus spp.). Depending on clinical suspicion, we will conduct a diagnostic approach that includes non-invasive tests (stains, cultures, and polymerase chain reactions —PCR— in sputum) and other invasive tests such as a bronchoscopy with bronchoalveolar lavage or a lung biopsy in order to make an etiological diagnosis and initiate targeted treatment.

Referencias bibliográficas

  • Di Pasquale MF, Sotgiu G, Gramegna A, Radovanovic D, Terraneo S, Reyes LF. Prevalence and etiology of community-acquired pneumonia in immunocompromised patients. Clin Infect Dis. 2019;68:1482-93.
  • Azoulay E, Russell L, Van de Louw A, Metaxa V, Bauer P, Povoa P. Diagnosis of severe respiratory infections in imunocompromised patients. Intensive Care Med. 2020;46:298-314.
  • Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2004;170:22-48.
  • Ramírez JA, Musher DM, Evans SE, De La Cruz C, Crothers KA. Treatment of community-acquired pneumonia in immunocompromised adults: A consensus statement regarding initial strategies. Chest. 2020;158:1896-911.
  • Dropulic LK, Lederman HM. Overview of Infections in the Immunocompromised Host. Microbiol Spectr. 2016;4:10.1128.
  • Nam HH, Ison MG. Community-acquired respiratory viruses in solid organ transplant. Curr Opin Organ Transplant. 2019;24:483-9.
  • Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909-17.
  • Avino LJ, Naylor SM, Roecker AM. Pneumocystis jirovecii Pneumonia in the non-HIV-infected population. Ann Pharmacother. 2016;50:673-9.
  • To K, Cao R, Yegiazaryan A, Owens J, Venketaraman V. General overview of nontuberculous mycobacteria opportunistic pathogens: Mycobacterium avium and Mycobacterium abscessus. J Clin Med. 2020;9:2541.
  • Chellapandian D, Lehrnbecher T, Phillips B, Fisher BT, Zaoutis TE, Steinbach WJ. Bronchoalveolar lavage and lung biopsy in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic review and meta-analysis. J Clin Oncol. 2015;33:501-9.
  • Ramos A, Pintos Pascual I, Múñez Rubio E. Protocolo diagnóstico y tratamiento empírico de la neumonía en el paciente inmunocomprometido. Medicine. Programa de formación médica continuada acreditado. 2018;12:3281-4
Fonte de datos: Dialnet